http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2350613-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1542e8802a0e6a7a8a7c6bd5627eb857 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 |
| filingDate | 2004-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2009-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_543ae79b8540aadcbd9bc9836348b079 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_798717cf82a910a779d59a02ba490b73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_379e21d9d1752e3748cf842c819dfa50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b11405f9bf1010bf5d7c67369c9c3dbe |
| publicationDate | 2009-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2350613-C2 |
| titleOfInvention | Substituted thiazolbenzoisothiazol dioxide derivatives, method of production and application |
| abstract | FIELD: chemistry; pharmacology. n SUBSTANCE: compounds of formula (I) as inhibitors of phosphotyrosine phosphotase 1B and their pharmaceutically acceptable salts, their application, based pharmaceutical composition and method of production. In general formula (I) , R1 indicates phenyl, naphthyl, thionaphthyl, pyridyl. Phenyl, naphthyl, thionaphthyl and pyridyl can be single- or multiple-substituted with F, Cl, Br, (CH 2 ) 0-2 OH, (C 1 -C 6 )-alkyl, (C 2 -C 6 )-alkenyl, (C 2 -C 6 )-alkinyl, CF 3 , OCF 3 , N(R9)(R10), piperidinone, piperazine, piperazinone, N-(C 1 -C 6 -alkylene)-piperazine, N-(C 1 -C 6 -alkylene)-piperazinone, morpholine, thiomorpholine, NO 2 , CN, O-(C 1 -C 6 )-alkyl, S(O) 0-2 -(C 1 -C 6 )-alkyl, SO 2 -N(R9)(R10), CO-(C 1 -C 6 )-alkyl, -COOH, (C 1 -C 6 )-alkylene-COOH, COO(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyleny-COO(C 1 -C 6 )-alkyl, (C 3 -C 10 )-cycloalkyl, phenyl. These piperidinone, piperazine, piperazinone, N-(C 1 -C 6 -alkylene)-piperazine, N-(C 1 -C 6 -alkylene)-piperazinone, morpholine, thiomorpholine, and phenyl rings can be single- or multiple-substituted with F, Cl, Br, (CH 2 ) 0-2 OH, COOH, CN, NO 2 , O-(C 1 -C 6 )-alkyl, -NH-O-(C 1 -C 6 )-alkyl, -(CO)-NH-O-(C 1 -C 6 )-alkylene-N(R9)(R10), -(CO)-(C 1 -C 6 )-alkyl, -(C 1 -C 6 )-alkyl, CF 3 , OCF 3 , N(R9)(R10); R2 indicates H, (C 1 -C 6 )-alkyl, COOH, (C 1 -C 6 )-alkylene-COOH, COO(C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkylene-COO(C 1 -C 6 )-alkyl; R3 indicates H, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkylenphenyl, -C(O)-phenyl, (C 1 -C 6 )-alkylenheterocycle, where heterocycle represents 5-6-merous heterocyclic ring containing 1-2 heteroatoms, chosen of nitrogen and oxygen, CO-(C 1 -C 6 )alkyl; R4, R5 indicate H; R6 indicates H, R9 indicates H, (C 1 -C 4 )-alkyl; R10 indicates H, (C 1 -C 4 )-alkyl. n EFFECT: applications for treating diseases mediated with phosphotyrosine phosphotase 1B activity, such as diabetes type II, lipidosis and carbohydrate metabolic imbalance, insulin resistivity, reduced sugar content in blood. n 9 cl, 2 tbl, 1 ex |
| priorityDate | 2003-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 531.